Cost of Weight Loss Medication Australia: 2026 Pricing & PBS Guide

Weight Loss Medication Cost Australia 2026: Wegovy, Mounjaro, Ozempic & Saxenda

Prescription weight loss medications are increasingly used in Australia as part of medically supervised weight management. However, the cost can be significant because medicines specifically used for weight loss are generally supplied on a private prescription rather than subsidised through the Pharmaceutical Benefits Scheme (PBS).

This guide explains the 2026 Australian landscape for Wegovy, Mounjaro, Ozempic and Saxenda, including TGA approval, PBS status, private prescription costs and how to access treatment safely.

Key Takeaways

1. Wegovy, Mounjaro and Saxenda are TGA-approved for chronic weight management in appropriate patients.
2. Wegovy is not currently PBS-subsidised for weight loss.
3. GLP-1 medicines are currently not PBS-subsidised specifically for weight loss.
4. Ozempic is primarily approved for Type 2 Diabetes Mellitus (T2DM) and should not be confused with Wegovy simply because both contain semaglutide.
5. Private medication prices vary between pharmacies, doses and products.
6. A doctor must determine whether prescription weight loss treatment is clinically appropriate.

Understanding Weight Loss Medications in Australia

Several prescription medicines are available for weight management in Australia.

Wegovy – Semaglutide

Wegovy is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist approved by the Therapeutic Goods Administration (TGA) for chronic weight management.

For adults, it is approved as an adjunct to a reduced-energy diet and increased physical activity for patients with an initial:

1. BMI (Body Mass Index) ≥30 kg/m²; or
2. BMI ≥27 kg/m² and <30 kg/m² with at least one weight-related comorbidity.

Mounjaro – Tirzepatide

Mounjaro is a dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 receptor agonist.

It is TGA-approved for both Type 2 Diabetes Mellitus and chronic weight management in appropriate patients.

Saxenda – Liraglutide

Saxenda is a GLP-1 receptor agonist administered by daily injection and is TGA-approved for chronic weight management in eligible patients.

Ozempic – Semaglutide

Ozempic also contains semaglutide but is primarily approved for Type 2 Diabetes Mellitus.

Although Ozempic and Wegovy contain the same active ingredient, they have different approved indications, doses and delivery systems and should not be considered interchangeable.

Are Weight Loss Medications Covered by the PBS in 2026?

GLP-1 medicines are not currently PBS-subsidised specifically for weight loss or obesity treatment in Australia.

This distinction is important because TGA approval does not mean that a medication is PBS-funded.

The TGA determines whether medicines can be supplied in Australia for particular indications.

The Pharmaceutical Benefits Advisory Committee (PBAC) separately assesses whether medicines should be recommended for government subsidy through the PBS.

The PBAC has considered GLP-1 medicines for obesity treatment, but patients should not interpret a PBAC application, consideration or recommendation as meaning that a medicine is already available at a PBS-subsidised price.

Until an applicable PBS listing actually takes effect, patients prescribed these medicines specifically for weight management should expect to pay the private pharmacy price.

Is Wegovy on the PBS?

No. Wegovy is not currently PBS-subsidised for weight management in Australia.

There is therefore currently no general $25 PBS Wegovy price for weight loss.

Patients should also not assume that having a BMI over 35, cardiovascular disease, previous myocardial infarction or stroke automatically makes them eligible for subsidised Wegovy.

Government consideration of funding for obesity medicines is ongoing, and PBS arrangements may change in the future.

TGA Approval vs PBS Subsidy

These terms are often confused.

TGA approval means that a medicine has been assessed and registered for specified indications in Australia.

PBS listing means the Australian Government subsidises the cost of the medicine for patients who satisfy the specific PBS restrictions.

A medicine can therefore be TGA-approved but not PBS-subsidised.

This is currently an important distinction for medicines prescribed specifically for weight management.

Private Weight Loss Medication Costs

Patients receiving weight loss medication on a private prescription pay the pharmacy's private price.

Costs can vary considerably according to:

1. Medication
2. Dose
3. Pharmacy
4. Manufacturer pricing
5. Stock availability
6. Dispensing arrangements

Because private prices can change, patients should confirm the current price directly with their pharmacy before starting treatment.

This is particularly important when considering long-term treatment because the cumulative annual cost can be substantial.

Wegovy Cost in Australia

Wegovy is generally supplied on a private prescription when used for weight management.

The cost can vary depending on dose and pharmacy.

Rather than relying on a fixed advertised price, patients should obtain an up-to-date quote from their pharmacy because private medicine prices are not necessarily uniform across Australia.

Mounjaro Cost in Australia

Mounjaro is also commonly supplied privately when prescribed for weight management.

Prices can vary according to the prescribed strength and pharmacy.

Patients should consider the potential cost of treatment over several months rather than only the initial prescription price.

Saxenda Cost in Australia

Saxenda is administered daily rather than weekly.

Like other medicines prescribed specifically for weight management, patients should check the current private pharmacy price before commencing treatment.

What About Ozempic?

Ozempic requires particular clarification.

Ozempic contains semaglutide but is primarily approved for Type 2 Diabetes Mellitus rather than chronic weight management.

Ozempic has PBS listings for specific eligible patients with diabetes, subject to PBS restrictions.

This does not mean Ozempic is PBS-subsidised simply because someone wants to use semaglutide for weight loss.

Patients should use the medication prescribed specifically for their clinical circumstances.

Who May Be Suitable for Prescription Weight Management Treatment?

Eligibility depends on the particular medication and the patient's individual circumstances.

For several TGA-approved weight management medicines, treatment may be considered in adults with:

1. BMI ≥30 kg/m²; or
2. BMI ≥27 kg/m² with an associated weight-related condition.

Examples of weight-related conditions may include hypertension, dyslipidaemia, obstructive sleep apnoea or abnormal glucose metabolism.

However, BMI alone does not determine whether a medication should be prescribed.

The treating doctor must consider medical history, current medications, contraindications, previous weight management attempts and potential risks and benefits.

Factors Affecting the Total Cost of Treatment

Medication is only one component of medically supervised weight management.

Patients may also need to consider:

1. Initial medical consultation
2. Follow-up consultations
3. Pharmacy dispensing costs
4. Pathology investigations where clinically indicated
5. Dose adjustments
6. Management of adverse effects
7. Other monitoring recommended by the treating doctor

Treatment costs should therefore be considered over the longer term rather than simply comparing the price of an individual prescription.

How to Access Medical Weight Management Through AussieScripts

AussieScripts provides telehealth consultations with Australian-registered doctors for patients seeking assessment for medical weight management.

Step 1 – Complete Your Assessment

Provide your current height, weight, medical history, medications and other relevant health information.

Step 2 – Doctor Review

An Australian-registered doctor reviews your information and assesses whether prescription weight management treatment is clinically appropriate.

Step 3 – Prescription if Clinically Appropriate

If the doctor determines that treatment is suitable, an eScript may be issued.

Patients can then have the prescription dispensed by an Australian pharmacy.

A prescription is not guaranteed and remains subject to the treating doctor's clinical assessment.

Frequently Asked Questions

Is Wegovy covered by the PBS in Australia in 2026?

No. Wegovy is not currently PBS-subsidised specifically for weight management.

Can I get Wegovy for $25 if my BMI is over 35?

Not currently for weight management. There is no active general PBS Wegovy weight-loss subsidy based simply on having a BMI over 35.

Is Wegovy approved for weight loss in Australia?

Yes. Wegovy is TGA-approved for chronic weight management in eligible patients